Humacyte (HUMA), a commercial-stage company, will collaborate with preclinical-stage firm Trestle Biotherapeutics to explore technology synergies for bioengineering vascularized organs for transplantation, Trestle Biotherapeutics said Thursday.
Trestle Bio said the research allows both companies to expand their own R&D programs while looking into the interaction of Trestle Bio's biofabricated human kidney tissues with Humacyte's acellular tissue engineered vessel-tyod.
Financial terms of the collaboration were not disclosed.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。